Aiming to expand its hepatology portfolio, UK pharma major GSK (LSE: GSK) yesterday announced that it has entered into an ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

Here are the five things you need to know in local business news to start your busy Thursday, including World Cup game prices, GSK's latest buy, how Cape Cod got its name and economic experts offer ...

Over the last few days, acquisition suitors of bluebird bio sweetened their offer, RA Capital and Khosla Ventures launched a ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

Health-care companies fell amid concerns about increased regulation and upheaval in the sector. UnitedHealth Group continued its retreat after the abrupt departure of its chief executive.

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

Aeva Technologies, a firm founded by former Apple engineers that makes sensors used in factories and self-driving vehicles, said it had sold a 6% stake for $50 million to an unnamed strategic partner ...